Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Synaptic vesicle glycoprotein 2A (SV2A) is a prototype synaptic vesicle protein regulating action potential-dependent neurotransmitters release. SV2A also serves as a specific binding site for certain antiepileptics and is implicated in the treatment of epilepsy. Here, to elucidate the role of SV2A in modulating epileptogenesis, we generated a novel rat model (Sv2aL174Q rat) carrying a Sv2a-targeted missense mutation (L174Q) and analyzed its susceptibilities to kindling development. Although animals homozygous for the Sv2aL174Q mutation exhibited normal appearance and development, they are susceptible to pentylenetetrazole (PTZ) seizures. In addition, development of kindling associated with repeated PTZ treatments or focal stimulation of the amygdala was markedly facilitated by the Sv2aL174Q mutation. Neurochemical studies revealed that the Sv2aL174Q mutation specifically reduced depolarization-induced GABA, but not glutamate, release in the hippocampus without affecting basal release or the SV2A expression level in GABAergic neurons. In addition, the Sv2aL174Q mutation selectively reduced the synaptotagmin1 (Syt1) level among the exocytosis-related proteins examined. The present results demonstrate that dysfunction of SV2A due to the Sv2aL174Q mutation impairs the synaptic GABA release by reducing the Syt1 level and facilitates the kindling development, illustrating the crucial role of SV2A-GABA system in modulating kindling epileptogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Its influence is particularly pronounced at inhibitory terminals, where it shapes GABA release and constrains network hyperexcitability [173,187,197].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Modification of seizure activity by electrical stimulation: I. after-discharge threshold
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90176-9 · Cited by 748
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
SV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Brain contains two forms of synaptic vesicle protein 2.
Bajjalieh, S. M., Peterson, K., Linial, M., & Scheller, R. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2150 · Cited by 197
Cited by
Keratan sulfate, a complex glycosaminoglycan with unique functional capability
Caterson, B., & Melrose, J. (2018) · Glycobiology · doi:10.1093/glycob/cwy003 · Cited by 249
“SV2 knockout mice lacking SV2A display abnormal neurotransmission and epileptic seizures (Crowder et al. 1999; Tokudome et al. 2016).”
BackgroundLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“These data agree with the observations of a great co-expression between SV2A and GABAergic neurons in the amygdala and hippocampus [163,164,166,167].”
ResultSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Vico Varela, E., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 118
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Klein, P., Friedman, A., Hameed, M. Q., Kaminski, R. M., Bar‐Klein, G., Klitgaard, H., Koepp, M. J., Jóźwiak, S., Prince, D. A., Rotenberg, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16450 · Cited by 102
Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes
Szpirer, C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00673-8 · Cited by 107
Bonnycastle, K., Davenport, E. C., & Cousin, M. A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15035 · Cited by 83
Li, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Synaptic vesicle protein 2: A multi-faceted regulator of secretion
Ciruelas, K., Marcotulli, D., & Bajjalieh, S. M. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.02.003 · Cited by 55
Cai, Z., Li, S., Zhang, W., Pracitto, R., Wu, X., Baum, E., Finnema, S. J., Holden, D., Toyonaga, T., Lin, S.-F., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00618 · Cited by 54
Distinct synaptic vesicle recycling in inhibitory nerve terminals is coordinated by SV2A
Bae, J. R., Lee, W., Jo, Y. O., Han, S., Koh, S., Song, W. K., & Kim, S. H. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101879 · Cited by 48
“Notably, SV2A expression level is correlated with epilepsy (Tokudome et al., 2016), such that a complete absence of SV2A causes severe epilepsy (Janz et al.”
BackgroundWood, M., Daniels, V., Provins, L., Wolff, C., Kaminski, R. M., & Gillard, M. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261149 · Cited by 44
“More recent studies have shown that SV2A dysfunction resulting from a missense mutation (L174Q) results in a selective reduction in GABAergic transmission, rendering animals carrying the mutation highly susceptible to seizures and markedly facilitating kindling (Tokudome et al., 2016a,b).”
BackgroundLuo, J., Norris, R. H., Gordon, S. L., & Nithianantharajah, J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.001 · Cited by 39
“Rats homozygous for a missense mutation (L174Q) in SV2A generated via a highthroughput mutation screen show increased seizure susceptibility and severity induced by PTZ kindling (Tokudome et al., 2016).”
Harper, C. B., Small, C., Davenport, E. C., Low, D. W., Smillie, K. J., Martínez-Mármol, R., Meunier, F. A., & Cousin, M. A. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0210-20.2020 · Cited by 38
“Importantly, SV2A is the primary paralog in GABAergic neurons (Ciruelas et al., 2019) and expression of SV2A is higher in GABAergic neurons when compared with glutamatergic neurons (Tokudome et al., 2016a,b).”
BackgroundInfluentialSp1 in Astrocyte Is Important for Neurite Outgrowth and Synaptogenesis
Hung, C.-Y., Hsu, T., Chuang, J., Su, T., Chang, W., & Hung, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01694-7 · Cited by 35
“Sv2 is involved in the regulation of vesicle trafficking and exocytosis in neurons [38, 39].”
BackgroundTokudome, K., Okumura, T., Terada, R., Shimizu, S., Kunisawa, N., Mashimo, T., Serikawa, T., Sasa, M., & Ohno, Y. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00210 · Cited by 31
“To explore the role of SV2A in the pathogenesis of epileptic disorders, we recently generated a novel rat model (Sv2aL174Q rat) carrying a missense mutation of the Sv2a gene and showed that the Sv2aL174Q rats were hypersensitive to kindling development (Tokudome et al., 2016).”
BackgroundMethodSelf-citationVanoye-Carlo, A., & Gómez-Lira, G. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.021 · Cited by 30
Kong, Y., Huang, L., Li, W., Liu, X., Zhou, Y., Liu, C., Zhang, S., Xie, F., Zhang, Z., Jiang, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.609908 · Cited by 29
“Therefore, targeting SV2A may provide a novel strategy for early diagnosis and treatment of AD (Kramer et al., 2004; Tokudome et al., 2016; Onwordi et al., 2020).”
BackgroundSynthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug
Gayke, M. S., Narode, H., Gyanchander, E., Bhosale, R. S., & Yadav, J. S. (2022) · ACS Omega · doi:10.1021/acsomega.1c05378 · Cited by 32
Loss of HCN1 subunits causes absence epilepsy in rats
Nishitani, A., Kunisawa, N., Sugimura, T., Sato, K., Yoshida, Y., Suzuki, T., Sakuma, T., Yamamoto, T., Asano, M., Saito, Y., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.004 · Cited by 32
Self-citationKamiński, K., Socała, K., Zagaja, M. P., Andres‐Mach, M., Abram, M., Jakubiec, M., Pieróg, M., Nieoczym, D., Rapacz, A., Gaweł, K., et al. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00773-w · Cited by 30
Adriana, P. M. L., Alcira, R. M. B., Jatziri, C. G. I., Zamudio, S., Luis, C. P. J., Berenice, S. H. K., & Griselda, M. T. J. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.01.004 · Cited by 27
Kindling: A Model and Phenomenon of Epilepsy
Sutula, T. P., & Kotloski, R. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00055-9 · Cited by 28
Contreras‐García, I. J., Gómez‐Lira, G., Phillips-Farfán, B. V., Pichardo‐Macías, L. A., García‐Cruz, M. E., Chávez-Pacheco, J. L., & Mendoza‐Torreblanca, J. G. (2021) · Brain Sciences · doi:10.3390/brainsci11050531 · Cited by 27
“This is relevant since several reports have shown preferential SV2A function on GABAergic neurotransmission [33], even during epilepsy [12,30,32].”
BackgroundSerikawa, T., Kunisawa, N., Shimizu, S., Kato, M., Iha, H. A., Kinboshi, M., Nishikawa, H., Shirakawa, Y., Voigt, B., Nakanishi, S., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111922 · Cited by 25
Self-citationContreras-García, I. J., Pichardo-Macías, L. A., Santana-Gómez, C. E., Sánchez-Huerta, K., Ramírez-Hernández, R., Gómez-González, B., Rocha, L., & Mendoza Torreblanca, J. G. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.023 · Cited by 18
Burrows, D. R. W., Diana, G., Pimpel, B., Moeller, F., Richardson, M. P., Bassett, D. S., Meyer, M. P., & Rosch, R. E. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0171-22.2023 · Cited by 23
“…et al., 2002; Buckmaster, 2014; Chu et al., 2010), the strengths of synapses (Geinisman et al., 1988; Poulter et al., 1999; Zhang et al., 2012), and the intrinsic excitability of neurons (Upreti et al., 2012; Tokudome et al., 2016; Vannini et al., 2020) linked to animal models of epilepsy.”
PET imaging of synaptic density in Parkinsonian disorders
Martin, S. L., Uribe, C., & Strafella, A. P. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25253 · Cited by 22
Farooq, T., Javaid, S., Ashraf, W., Rasool, M. F., Anjum, S. M. M., Sabir, A., Ahmad, T., Alqarni, S. A., Alqahtani, F., & Imran, I. (2024) · ACS Omega · doi:10.1021/acsomega.4c00962 · Cited by 15
“The SV2A-GABA system has been associated with kindling progression as Tokudome et al. reported that as SV2A protein modulates GABA release 47 and its dysfunction leads to impaired release of synaptic GABA in the hippocampus, leading to elevated susceptibility of rodents to PTZ kindling.”
BackgroundBhamare, P., Pothuvan, U., Upmanyu, N., & Dubey, R. (2020) · Analytical Methods · doi:10.1039/c9ay02582k · Cited by 15
Zhang, Y., Heylen, L., Partoens, M., Mills, J. D., Kaminski, R. M., Godard, P., Gillard, M. R., de Witte, P. A. M., & Siekierska, A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.881933 · Cited by 16
“Similarly, homozygous rats carrying an SV2A-targeted missense mutation exhibited normal development but were susceptible to PTZ induced-seizures and kindling development (Tokudome et al., 2016).”
BackgroundAnxiety-like features and spatial memory problems as a consequence of hippocampal SV2A expression
Navacerrada, M. E. S., Bartholomé, O., den Ackerveken, P. V., Ferrara, A., Rogister, B., Plenevaux, A., & Tirelli, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217882 · Cited by 15
Gabapentin Inhibits Multiple Steps in the Amyloid Beta Toxicity Cascade
González-Sanmiguel, J., Burgos, C. F., Bascuñán, D., Fernández-Pérez, E. J., Riffo-Lepe, N., Boopathi, S., Fernández-Pérez, A., Bobadilla, C., González, W., Figueroa, M., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00414 · Cited by 14
Inglis, G. A. S., Zhou, Y., Patterson, D. G., Scharer, C. D., Han, Y., Boss, J. M., Wen, Z., & Escayg, A. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa150 · Cited by 12
Clinical Use and Monitoring of Antiepileptic Drugs
Knezevic, C. E., & Marzinke, M. A. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2017.023689 · Cited by 18
“Valproic acid and felbamate are both thought to combine a GABA-related mechanism and N-methyl-D-aspartate (NMDA) signal inhibition.”
BackgroundInfluentialDrug Treatment of Epilepsy: From Serendipitous Discovery to Evolutionary Mechanisms
Lou, S., & Cui, S. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210910124727 · Cited by 14
Zhou, J., Liang, W., Wang, J., Chen, J., Liu, D., Wang, X., Wu, Y., Zhang, Q., & Shen, D. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab338 · Cited by 11
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 13
“In addition, SV2A dysfunction can activate NMDAR, and cause calcium overload and continue to generate action potentials (Tokudome et al., 2016).”
BackgroundDrongitis, D., Caterino, M., Verrillo, L., Santonicola, P., Costanzo, M., Poeta, L., Attianese, B., Barra, A., Terrone, G., Lioi, M. B., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac028 · Cited by 14
“Similarly, in Arx (GCG)7/Y , three (i.e. Profilin-2, PFN2; synaptic vesicle glycoprotein 2A , SV2A; and sodium/calcium exchanger 1, SLC8A1) are involved in cytoskeleton and vesicle trafficking (Supplementary Material, Table S8) (39–41).”
Hayase, Y., Amano, S., Hashizume, K., Tominaga, T., Miyamoto, H., Kanno, Y., Ueno-Inoue, Y., Inoue, T., Yamada, M., Ogata, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01082-6 · Cited by 10
Self-citationGonzález-H, G., Contreras‐García, I. J., Sánchez-Huerta, K., Queiroz, C. M., Gudiño, L. R. G., Mendoza‐Torreblanca, J. G., & Zamudio, S. (2020) · Brain Sciences · doi:10.3390/brainsci10090634 · Cited by 9
“γ-aminobutyric acid (GABA) release in the hippocampus [55,56].”
BackgroundGreen, S. L., Silvester, E. J., Dworkin, S., Shakya, M., Klein, A. R., Lowe, R. G. T., Datta, K. K., & Holland, A. (2024) · Aquatic Toxicology · doi:10.1016/j.aquatox.2024.106963 · Cited by 8
Li, C., Wang, Z., Ren, M., Ren, S., Wu, G., & Wang, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14778 · Cited by 9
“39 However, the mechanism via which SV2A loss translates into epilepsy and phar-macoresistance remains unclear.”
BackgroundTakahashi, S., Takechi, K., Jozukuri, N., Niimura, T., Chuma, M., Goda, M., Zamami, Y., Izawa‐Ishizawa, Y., Imanishi, M., Horinouchi, Y., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174099 · Cited by 8
Hogg, J. A., & Cousin, M. A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.16308 · Cited by 5
Tanaka, M., Fujikawa, R., Sekiguchi, T., Hernandez, J., Johnson, O. T., Tanaka, D., Kumafuji, K., Serikawa, T., Trung, H. H., Hattori, K., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1263724 · Cited by 6
“The F344-Sv2a m1Kyo rats were generated by a gene-driven N-ethyl-N-nitrosourea mutagenesis (Mashimo et al., 2008) and carried a missense mutation (L174Q) in the synaptic vesicle glycoprotein 2A ( Sv2a ) gene on a F344/NSlc background (Tokudome et al., 2016).”
MethodSelf-citationWisłowska-Stanek, A., Turzyńska, D., Sobolewska, A., Kołosowska, K., Szyndler, J., Skórzewska, A., & Maciejak, P. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00573-w · Cited by 5
Han, S., Gilmartin, M. R., Sheng, W., & Jin, V. X. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.01.028 · Cited by 5
Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain
Mikkelsen, J. D., Aripaka, S. S., Bascuñana, P., Bankstahl, M., Bankstahl, J. P., & Pazarlar, B. A. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.07.020 · Cited by 5
“In these animals, depolarization-induced c-aminobutyric acid (GABA) release, but not glutamate, was reduced in the hippocampus (Tokudome et al., 2016).”
InfluentialFunction of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy
Tokudome, K., Shimizu, S., Serikawa, T., & Ohno, Y. (2018) · Folia Pharmacologica Japonica · doi:10.1254/fpj.152.275 · Cited by 7
Self-citationHow to Find Candidate Drug-targets for Antiepileptogenic Therapy?
Yu, N., Lin, X., & Di, Q. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200128124338 · Cited by 6
Levetiracetam: An antiseizure drug with unique neuroprotective properties
Ewens, A. N., & Thayer, S. A. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100006 · Cited by 5
Liu, Z., Idris, N. F. B., Liu, L., Hou, C., Yang, C., Zhan, C., Liang, S., Shen, J., Lu, K., Hu, H., et al. (2025) · Insects · doi:10.3390/insects16030251 · Cited by 1
“Previous studies have demonstrated that SV2A and SV2B , which are specifically expressed in synaptic vesicles, can regulate action potential-dependent neurotransmitter GABA release and the density of GABAergic neuron signals in mammals [36–38].”
Khattar, N., Matuskey, D., Gallezot, J., Naganawa, M., Holmes, S. E., Sadabad, F. E., Mayeli, M., Esterlis, I., van Dyck, C. H., Mecca, A. P., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261441071 · Cited by 3
Synaptic Vesicle Glycoprotein 2A and Epilepsy
Hanaya, R., Hosoyama, H., & Arita, K. (2018) · てんかん研究 · doi:10.3805/jjes.36.3 · Cited by 1
Khattar, N., Matuskey, D., Gallezot, J., Naganawa, M., Holmes, S. E., Sadabad, F. E., Mayeli, M., Esterlis, I., van Dyck, C. H., Mecca, A. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.15.682460 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
T‐type Ca2+ channel activity increases in rat hippocampal CA1 region during kindling epileptogenesis
Aksöz, E., Sara, Y., & Onur, R. (2020) · Synapse · doi:10.1002/syn.22155
“…studies revealed a number of potential drug targets aiming to prevent epileptogenesis, directing neuroinflammation (Aksoz, 2018; Dey, Kang, Qiu, Du, & Jiang, 2016; Vezzani, 2015), synaptic vesicle proteins (Tokudome et al., 2016), and T-type Ca2+ channels (Powell, Cain, Snutch, & O'Brien, 2014).”
BackgroundSabatier, L. (2020) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/93992
Shimomura, H., Minagawa, K., Mine, J., Lee, T., Mure, C., Taniguchi, N., Tokunaga, S., Tanaka, Y., Okuda, M., Kikuchi, S., et al. (2021) · Epilepsy & Seizure · doi:10.3805/eands.13.70
Boychuk, J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00209-7
(2023) · Neurotherapeutics · doi:10.1007/13311.1878-7479
Descubrimiento de nuevos anticonvulsivos que actúan mediante interacciones con canales iónicos
Llanos, M. A. (2022) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/140503
Garofalo, F. M. (2022) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/163663
Decomposing SV2A Function and Dysfunction one Neuron at a Time
Safari, M., & Weston, M. C. (2025) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597251352976
“A previous paper used a knockin rat model 9 to demonstrate that an SV2A mutation selectively impaired depolarization-induced GABA release in the hippocampus while depolarization-induced glutamate release remained unaffected.”
The Role of Brivaracetam in the Management of Childhood Epilepsy
Jiang, W., Xiao, F., Zhao, F., Zhu, S., & Zhang, H. (2025) · Journal of Child Neurology · doi:10.1177/08830738251405693
“9 These neurotransmitters release affect generation of action potentials in the nerves, which indicates that SV2A was a key regulator in the process of epileptogenesis.”
Hayase, Y., Amano, S., Hashizume, K., Tominaga, T., Miyamoto, H., Kanno, Y., Ueno-Inoue, Y., Inoue, T., Yamada, M., Ogata, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13311052
Self-citationExperience With Brivaracetam in the Acute Care Setting at a Large Tertiary Care Center
Cormier, J., Traner, C. B., Subramaniam, T., Garcia, G. E., Hirsch, L. J., Ammar, A. A., & Gilmore, E. J. (2026) · The Neurohospitalist · doi:10.1177/19418744261422335
“1,2 The SV2A protein is highly expressed throughout the brain and regulates action potential-dependent neurotransmitter release, 3 and multiple studies have shown a strong association between SV2A binding and anti-seizure effect in animal models of epilepsy.”
In vitro and in vivo study of the effects of Levetiracetam on activated microglia during sepsis
Fleurance, R. (2021) · theses.fr (ABES) · doi:10.70675/0a82ed6ez6595z4366z832fz70cbe839c7ff
Basuli, F., Shi, J., Zhang, X., & Swenson, R. E. (2026) · Molecules · doi:10.3390/molecules31132396
“Due to its ubiquitous expression throughout gray matter regions, SV2A has emerged as a promising marker of synaptic density, motivating the development of molecules derived from the anti-epileptic drug levetiracetam [(S)- α -ethyl-2- oxo-pyrrolidine acetamide], commercially known as Keppra ® [4–6].”
Mori, T., Terashima, H., Kakimoto, Y., Kato, M., & Uchino, S. (2026) · Epileptic Disorders · doi:10.1002/epd2.70339
Bridging the Gap: Harnessing Phytochemical-Loaded Nanocarriers for Enhanced Epilepsy Treatment
Kazemi, M., Arab, F., Nasiri, A., Besharatiyan, F., & Jahani, R. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06147-6
SV2A attenuates interictal anxiety in pharmacoresistant epilepsy via the SYT3–GluA2 axis
Li, C., Pan, T., Ren, M., Wang, X., Shi, Y., Ren, S., 伍国锋, & Wang, L. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111206
Metadata
- Authors
- Tokudome, K., Okumura, T., Shimizu, S., Mashimo, T., Takizawa, A., Serikawa, T., Terada, R., Ishihara, S., Kunisawa, N., Sasa, M., & Ohno, Y.
- Affiliations
- Osaka University of Pharmaceutical Sciences (JP)
- Kyoto University (JP)
- Corresponding author
- Ohno, Yukihiro
- Venue
- Scientific Reports
- Published
- 2016-06-06
- Volume
- 6
- Issue
- 1
- Pages
- 27420-27420
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4893657
- OpenAlex
- W2474320719
- Cited by
- 75
- References
- 36
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 15 · 2019: 10 · 2018: 7 · 2017: 3 · 2016: 1
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Japan Agency for Medical Research and Development (15ek0109120s0701)
- Ministry of Education, Culture, Sports, Science and Technology (15H04892, 26460111)
- Japan Society for the Promotion of Science (26460111)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- SV2A, kindling, epileptogenesis, GABAergic neurotransmission, GABA release, synaptotagmin-1, pentylenetetrazole-induced seizures, missense mutations, amygdala stimulation, hippocampus, exocytosis
- MeSH terms
- Amino Acid Sequence, Amygdala, Animals, Epilepsy, gamma-Aminobutyric Acid, Hippocampus, Humans, Kindling, Neurologic, Male, Membrane Glycoproteins, Nerve Tissue Proteins, Synaptic Transmission, Rats, Inbred F344, Synaptic Vesicles, Sequence Homology, Amino Acid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.